Macy-Pan

Overview

Macy-Pan is a Shanghai-based hyperbaric chamber manufacturer founded in 2009, with what is, by published catalog count, the widest product range of any single HBOT manufacturer: 13 or more configurations spanning ultra-budget soft-shell units at 1.3 ATA through sitting-position mid-tier models, wheelchair-accessible roll-in designs, and clinical-grade hard-shell chambers rated to 2.0 ATA. That breadth — combined with manufacturer-direct pricing in the $2,500–$5,000 USD range FOB China — gives Macy-Pan a structural cost advantage over US-domestic alternatives in most tiers.

The critical regulatory caveat applies to every tier equally: Macy-Pan chambers are not FDA-cleared for the US market. In the United States, they are sold for wellness use only. If you are a US buyer seeking a chamber for a physician-prescribed medical indication — wound healing, carbon monoxide poisoning, decompression sickness, or any other FDA-recognized HBOT use — you need an FDA-cleared device and a clinical setting. Macy-Pan does not satisfy that requirement.

For international buyers, clinics in markets without US FDA requirements, spas, wellness centers, and cost-priority home users who have consulted a physician and understand the off-label context, Macy-Pan’s range represents genuine value. This review assesses the product line on published specifications, certifications, and positioning — not on therapeutic outcomes, which are not assessed here.

Safety notice: Consult a physician before using hyperbaric oxygen therapy in any form. Contraindications include certain ear and lung conditions, untreated pneumothorax, and recent ear surgery, among others. HBOT at any pressure is a medical procedure and should be approached as such.

Product line at a glance

Macy-Pan’s catalog spans two physically distinct chamber types with meaningfully different pressure ceilings, evidence bases, and use contexts.

Tier	Shell type	Max pressure	Typical application	Approx. price (FOB)
Entry soft-shell	Soft (flexible urethane)	1.3 ATA	Home wellness, recovery	~$2,500
Mid soft-shell	Soft (heat-welded)	1.3–1.5 ATA	Spa, clinic supplement	~$3,000–$3,800
MC4000 wheelchair	Soft, roll-in ramp	1.3 ATA	Accessible/clinical use	~$3,500–$4,500
Hard-shell clinical	Steel/acrylic hard-shell	Up to 2.0 ATA	Clinical, institutional	~$4,500–$5,000+

Certifications across the line: CE (EU medical device), ISO 13485 (medical device quality management), ISO 9001 (general quality management), and SGS (third-party inspection and testing). No FDA 510(k) clearance is held for any US-market Macy-Pan product.

Soft-shell vs hard-shell: the distinction that matters most

The most important specification decision when evaluating any hyperbaric chamber — Macy-Pan or otherwise — is whether the chamber operates at soft-shell pressures (~1.3 ATA) or hard-shell pressures (1.5 ATA and above, up to 2.0 ATA in Macy-Pan’s clinical line, or 2.4+ ATA in hospital-grade systems).

Soft-shell chambers at 1.3 ATA use flexible construction that constrains maximum pressure by design. The mild pressure increase (roughly equivalent to 11 feet / 3.3 metres of seawater depth) delivers a modest elevation in dissolved oxygen in blood plasma. The published evidence base at 1.3 ATA is smaller and more recent than the hard-shell literature; most published research involves recovery, post-concussion wellness contexts, and similar applications. 1.3 ATA soft-shell chambers are widely sold as wellness devices in consumer and spa markets worldwide.

Hard-shell chambers at 1.5–2.0 ATA use rigid steel or acrylic construction that can sustain higher pressures. Most of the published clinical HBOT literature — including for the FDA-recognized medical indications (wound healing, decompression sickness, carbon monoxide poisoning, diabetic foot ulcers, radiation injury, and others) — uses 2.0–2.5 ATA in hospital or clinic-grade hard-shell settings. Macy-Pan’s hard-shell line reaches 2.0 ATA, overlapping the lower end of that clinical-evidence pressure range.

Neither pressure tier is without value. The buyer should understand which tier maps to their intended context — and should confirm that context with a physician.

Key features

Construction and certifications

Macy-Pan’s published construction method is heat-welded assembly without adhesive bonding — a process the manufacturer describes as non-toxic and glue-free. This construction approach eliminates off-gassing concerns from solvent-based adhesives, which is a relevant consideration in an enclosed pressurized environment where a user may spend 60–90 minutes per session.

Third-party certifications include ISO 13485 (the international standard for quality management systems specific to medical devices), ISO 9001 (general quality management), CE marking for European market medical devices, and SGS verification. These certifications indicate that the manufacturing process has been audited against defined quality standards — they do not constitute regulatory clearance for medical use in the United States or a clinical efficacy claim.

Wheelchair-accessible MC4000 configuration

The MC4000 model is notable in the consumer and clinical-support HBOT market because it includes a roll-in ramp allowing wheelchair users to enter without transfer. This is an uncommon feature at this price point — most consumer and mid-tier clinical chambers require users to lie down and enter through an end aperture. For spas, rehabilitation clinics, and users with mobility limitations, the MC4000 addresses a real accessibility gap that most competitors at this tier do not.

Range and international distribution

Macy-Pan ships to 126 or more countries and positions itself as a manufacturer-direct supplier rather than a distributor-routed brand. For international buyers in markets where US FDA clearance is not the operative regulatory framework, this distribution model can offer meaningful cost advantages. For US buyers, FOB (free on board) China pricing means the listed price excludes international freight, import duties, and customs clearance — costs that should be modelled explicitly before comparing to a US-domestic delivered price.

Regulatory status and safety

FDA clearance status: Not cleared. Macy-Pan does not hold a US FDA 510(k) clearance for any model in its product line. In the United States, these chambers may be sold for wellness purposes; they are not legally marketed for any medical indication. This is distinct from brands such as OxyHealth (K041007), Newtowne, and Summit to Sea, which hold clearances for their respective models.

FDA 510(k) clearance is a “substantial equivalence” pathway, not an efficacy endorsement — but it is the operative standard in the US for marketing a hyperbaric chamber as a medical device. Buyers seeking clearance for HSA/FSA reimbursement, physician prescription fulfillment, insurance documentation, or clinic-grade deployment in the US should confirm clearance status independently via accessdata.fda.gov.

CE marking (claimed by Macy-Pan) is the EU medical device conformity marking and indicates compliance with applicable EU directives or regulations — relevant for buyers in European Economic Area markets. CE marking requirements differ from FDA clearance; a CE-marked product is not automatically FDA-cleared, and vice versa.

Contraindications and physician consultation are mandatory before use. Known contraindications to hyperbaric oxygen therapy include untreated pneumothorax, certain ear and sinus conditions (particularly in users who cannot equalize pressure), severe congestive heart failure in some presentations, and some pulmonary conditions. Individuals on certain medications may face elevated oxygen toxicity risk at higher pressures. Neither soft-shell nor hard-shell HBOT is appropriate as an unsupervised self-treatment for any condition. Consult a physician before purchasing or using any hyperbaric chamber.

Safety framing on wellness claims: Marketing for soft-shell 1.3 ATA chambers in the consumer space frequently references “recovery,” “performance,” and similar wellness framings. These are not FDA-recognized therapeutic claims for this device class, and the published evidence for wellness outcomes at 1.3 ATA is more limited than for clinical HBOT at higher pressures. The Atlas position: be a careful reader of claims in this category — weight peer-reviewed evidence over influencer testimonials or brand marketing copy, including ours.

Where it fits

Consider Macy-Pan if:

• You are an international buyer in a market where US FDA clearance is not the operative regulatory standard.
• You are a spa or wellness center sourcing mid-tier soft-shell chambers and your regulatory context permits non-FDA-cleared devices.
• You need a wheelchair-accessible chamber (MC4000) and US alternatives at this price point do not offer roll-in accessibility.
• You want access to a hard-shell 2.0 ATA unit at below-US-domestic pricing, are willing to manage FOB shipping and customs, and have confirmed your use context with a physician.
• Budget is the primary constraint and you have independently verified that the applicable regulatory framework in your market permits purchase and use.

Look elsewhere if:

• You are a US buyer who needs FDA clearance — for HSA/FSA, insurance, or physician-prescribed medical use. Consider OxyHealth (K041007), Newtowne, or Summit to Sea.
• You want a soft-shell 1.3 ATA chamber for US home use and want FDA clearance at competitive pricing. Newtowne’s entry-level FDA-cleared models start below Macy-Pan’s US landed cost for comparable configurations.
• US-based warranty service and English-language technical support matter to your use case.
• You are evaluating based on published clinical evidence for specific medical conditions — that evidence corresponds to clinical-grade HBOT at 2.0–2.4 ATA in supervised settings, not to consumer soft-shell wellness chambers at any brand.

Verdict

Macy-Pan earns a conditional 6.5/10 verdict. The product line is genuinely broad — 13+ configurations, two distinct pressure tiers, a wheelchair-accessible model, and meaningful certifications (ISO 13485, CE, SGS) position it as a credible international supplier for wellness and clinical-support applications outside the US regulatory framework. The manufacturer-direct model and FOB pricing deliver real cost advantages for buyers who can absorb shipping and customs costs.

The conditional rating reflects the structural trade-offs that US buyers in particular cannot sidestep: no FDA clearance, limited US service infrastructure, and quality-perception concerns that are not fully resolvable without independent third-party testing — which this review has not conducted. For the right buyer in the right market context, Macy-Pan is a legitimate option. For US buyers prioritizing regulatory standing, look at cleared domestic alternatives first.

Changelog

• 2026-06-15: Expanded review — full product-line breakdown, soft vs hard-shell distinction, regulatory status section, safety framing, and where-it-fits assessment added. Frontmatter updated per June 2026 content standards.
• 2026-05-07: Initial stub review published based on Macy-Pan published specifications, China manufacturing positioning, and widest-range product line documentation.